Concordance of HER2-low scoring in breast carcinomas among pathologists

Abstract The results from DESTINY-Breast 04 and the subsequent introduction of trastuzumab-deruxtecan as a potential treatement for HER2-low breast cancer necessitated the reevaluation of HER2 scoring. The discordance in HER2 scoring reported in previous studies led us to initiate a regional ring st...

Szczegółowa specyfikacja

Opis bibliograficzny

Główni autorzy:	Snježana Tomić, Tatjana Kapicl Ivković, Marija Milković Periša, Duško Đunđerović, Maja Jovičić Milentijević, Svetlana Oprić, Slobodanka Mitrović, Irena Jovanić, Savelina Popovska, Svitlana Bachurska, Desislava Tashkova, Kalin Kalchev, Ljiljana Vučković, Manuela Avirović, Emina Babarović, Melita Perić Balja, Čedna Tomasović-Lončarić, Jasmina Rajc, Irena Zagorac, Davor Oršolić, Toni Čeprnja
Format:	Artigo
Język:	Inglês
Wydane:	Nature Portfolio 2025-07-01
Seria:	Scientific Reports
Hasła przedmiotowe:	Breast cancer HER2-low Trastuzumab-deruxtecan
Dostęp online:	https://doi.org/10.1038/s41598-025-09839-6
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!